Patents by Inventor Douglas T. Ross

Douglas T. Ross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS
    Publication number: 20230296584
    Abstract: Presented herein are systems and methods for prediction, and especially automated prediction, of subject response to cancer therapies. Also presented herein are methods for selection of cancer therapies based upon predicted subject response and/or technologies for administering cancer therapies to appropriate subjects.
    Type: Application
    Filed: August 2, 2021
    Publication date: September 21, 2023
    Inventors: Robert Scott Seitz, David Hout, Tyler Jon Nielsen, Brock Lloyd Schweitzer, Brian Z. Ring, Douglas T. Ross
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20150198599
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 16, 2015
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • TLE3 as a marker for chemotherapy
    Patent number: 9005900
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: April 14, 2015
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • TLE3 as a marker for chemotherapy
    Patent number: 8785156
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: November 27, 2012
    Date of Patent: July 22, 2014
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8697373
    Abstract: Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: April 15, 2014
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8440410
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: September 10, 2010
    Date of Patent: May 14, 2013
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 8399622
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: March 19, 2013
    Assignee: Clarient Diagnostic Services, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20120065107
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: November 18, 2011
    Publication date: March 15, 2012
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • Identification of thymically derived CD4 T cells by protein tyrosine kinase 7 expression
    Patent number: 7960125
    Abstract: The invention provides methods of identifying naïve T cells by expression of PTK7.
    Type: Grant
    Filed: September 25, 2008
    Date of Patent: June 14, 2011
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: David B. Lewis, Christopher Haines, Thierry Giffon, Xiaowei Lu, Marc Tessier-Lavigne, Douglas T. Ross
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20110015259
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: September 24, 2010
    Publication date: January 20, 2011
    Applicant: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20110003709
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: September 10, 2010
    Publication date: January 6, 2011
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 as a marker for chemotherapy
    Patent number: 7816084
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: October 19, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 7811774
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: January 14, 2008
    Date of Patent: October 12, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 as a marker for chemotherapy
    Patent number: 7754431
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: July 13, 2010
    Assignee: Applied Genomics, Inc.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY
    Publication number: 20100143947
    Abstract: Methods and reagents for classifying HER2+ breast tumors and for identifying new HER2+ breast tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of HER2+ breast cancer.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 10, 2010
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20100062444
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: October 13, 2009
    Publication date: March 11, 2010
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • IDENTIFICATION OF THYMICALLY DERIVED CD4 T CELLS BY PROTEIN TYROSINE KINASE 7 EXPRESSION
    Publication number: 20090170101
    Abstract: The invention provides methods of identifying naïve T cells by expression of PTK7.
    Type: Application
    Filed: September 25, 2008
    Publication date: July 2, 2009
    Inventors: David B. Lewis, Christopher Haines, Thierry Giffon, Xiaowei Lu, Marc Tessier-Lavigne, Douglas T. Ross
  • TLE3 AS A MARKER FOR CHEMOTHERAPY
    Publication number: 20090155798
    Abstract: Methods of using TLE3 as a marker for predicting the likelihood that a patient's cancer will respond to chemotherapy. Methods of using TLE3 as a marker for selecting a chemotherapy for a cancer.
    Type: Application
    Filed: November 25, 2008
    Publication date: June 18, 2009
    Applicant: APPLIED GENOMICS, INC.
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Rodney A. Beck
  • Reagents and methods for use in cancer diagnosis, classification and therapy
    Patent number: 7504225
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: March 17, 2009
    Assignees: Applied Genomics, Inc., The UAB Research Foundation
    Inventors: Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, Tyler O. Kirby, Warner Huh
  • Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
    Publication number: 20080199891
    Abstract: Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer.
    Type: Application
    Filed: January 14, 2008
    Publication date: August 21, 2008
    Inventors: Brian Z. Ring, douglas T. Ross, Robert S. Seitz